Theme 3: HIV-1 drug resistance and treatment response
We are interested in typing the HIV-1 therapeutic response, drug resistance mutations and it’s dynamics in low- and middle-income countries.
Despite successful cART, resistance to a key HIV drug is common worldwide. Our study also aims to understand the subtype-specific differences in the evolution of drug resistance and treatment response. Using several cohorts from Europe, Asia, and Africa, we try to understand the role of naturally occurring polymorphisms in the drug target sites of cART drugs of class reverse transcriptase inhibitors, protease inhibitors, and integrase inhibitors in treatment response. We use technologies like deep-profiling by high throughput sequencing, in vitro and ex vivo phenotypic assays, biochemical and structural biology assays.